{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:38:23Z","timestamp":1788446303669,"version":"build-2803163510"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005155","name":"Azrieli Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["2054\/22"],"award-info":[{"award-number":["2054\/22"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["3605\/21"],"award-info":[{"award-number":["3605\/21"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Genet"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41588-025-02255-6","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T09:02:23Z","timestamp":1752742943000},"page":"1812-1822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic strategies for fragile X syndrome and implications for other gene-silencing disorders"],"prefix":"10.1038","volume":"57","author":[{"given":"Aseel","family":"Gadban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6355-9499","authenticated-orcid":false,"given":"Keith M.","family":"Gunapala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3497-5976","authenticated-orcid":false,"given":"Verdon","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8234-2685","authenticated-orcid":false,"given":"Nissim","family":"Benvenisty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"2255_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/ng.499","volume":"42","author":"SB Ng","year":"2010","unstructured":"Ng, S. B. et al. Exome sequencing identifies the cause of a Mendelian disorder. Nat. Genet. 42, 30\u201335 (2010).","journal-title":"Nat. Genet."},{"key":"2255_CR2","doi-asserted-by":"publisher","first-page":"R102","DOI":"10.1093\/hmg\/ddv259","volume":"24","author":"F Zhang","year":"2015","unstructured":"Zhang, F. & Lupski, J. R. Non-coding genetic variants in human disease. Hum. Mol. Genet. 24, R102\u2013R110 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"2255_CR3","first-page":"a019497","volume":"8","author":"HY Zoghbi","year":"2016","unstructured":"Zoghbi, H. Y. & Beaudet, A. L. Epigenetics and human disease. Cold Spring Harb. Perspect. Biol. 8, a019497 (2016).","journal-title":"Cold"},{"key":"2255_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41580-021-00382-6","volume":"22","author":"I Malik","year":"2021","unstructured":"Malik, I., Kelley, C. P., Wang, E. T. & Todd, P. K. Molecular mechanisms underlying nucleotide repeat expansion disorders. Nat. Rev. Mol. Cell Biol. 22, 589\u2013607 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2255_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-023-00443-4","volume":"9","author":"T Eggermann","year":"2023","unstructured":"Eggermann, T. et al. Imprinting disorders. Nat. Rev. Dis. Primers 9, 33 (2023).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2255_CR6","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1002\/ajmg.a.36264","volume":"161A","author":"E Tabolacci","year":"2013","unstructured":"Tabolacci, E. & Chiurazzi, P. Epigenetics, fragile X syndrome and transcriptional therapy. Am. J. Med. Genet. A 161A, 2797\u20132808 (2013).","journal-title":"Am. J. Med. Genet. A"},{"key":"2255_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.65","volume":"3","author":"RJ Hagerman","year":"2017","unstructured":"Hagerman, R. J. et al. Fragile X syndrome. Nat. Rev. Dis. Primers 3, 17065 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2255_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ajhg.2009.09.007","volume":"85","author":"B Coffee","year":"2009","unstructured":"Coffee, B. et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am. J. Hum. Genet. 85, 503\u2013514 (2009).","journal-title":"Am. J. Hum. Genet."},{"key":"2255_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41583-021-00432-0","volume":"22","author":"JD Richter","year":"2021","unstructured":"Richter, J. D. & Zhao, X. The molecular biology of FMRP: new insights into fragile X syndrome. Nat. Rev. Neurosci. 22, 209\u2013222 (2021).","journal-title":"Nat. Rev. Neurosci."},{"key":"2255_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fnmol.2018.00041","volume":"11","author":"R Dahlhaus","year":"2018","unstructured":"Dahlhaus, R. Of men and mice: modeling the fragile X syndrome. Front. Mol. Neurosci. 11, 41 (2018).","journal-title":"Front. Mol. Neurosci."},{"key":"2255_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2217\/rme-2016-0100","volume":"12","author":"D Vershkov","year":"2017","unstructured":"Vershkov, D. & Benvenisty, N. Human pluripotent stem cells in modeling human disorders: the case of fragile X syndrome. Regen. Med. 12, 53\u201368 (2017).","journal-title":"Regen. Med."},{"key":"2255_CR12","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/humu.22699","volume":"35","author":"D Kumari","year":"2014","unstructured":"Kumari, D. et al. Identification of fragile X syndrome-specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs. Hum. Mutat. 35, 1485\u20131494 (2014).","journal-title":"Hum. Mutat."},{"key":"2255_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13148-016-0181-x","volume":"8","author":"S Brasa","year":"2016","unstructured":"Brasa, S. et al. Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome. Clin. Epigenetics 8, 15 (2016).","journal-title":"Clin. Epigenetics"},{"key":"2255_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-6-2","volume":"6","author":"PH Schwartz","year":"2005","unstructured":"Schwartz, P. H. et al. Neural progenitor cells from an adult patient with fragile X syndrome. BMC Med. Genet. 6, 2 (2005).","journal-title":"BMC Med. Genet."},{"key":"2255_CR15","first-page":"107","volume":"17","author":"A Bhattacharyya","year":"2008","unstructured":"Bhattacharyya, A. et al. Normal neurogenesis but abnormal gene expression in human fragile X cortical progenitor cells. Stem Cells Dev. 17, 107\u2013117 (2008).","journal-title":"Stem"},{"key":"2255_CR16","doi-asserted-by":"publisher","first-page":"17834","DOI":"10.1073\/pnas.0508995102","volume":"102","author":"M Castr\u00e9n","year":"2005","unstructured":"Castr\u00e9n, M. et al. Altered differentiation of neural stem cells in fragile X syndrome. Proc. Natl Acad. Sci. USA 102, 17834\u201317839 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2255_CR17","doi-asserted-by":"publisher","DOI":"10.1242\/dev.156059","volume":"146","author":"K Obernier","year":"2019","unstructured":"Obernier, K. & Alvarez-Buylla, A. Neural stem cells: origin, heterogeneity and regulation in the adult mammalian brain. Development 146, dev156059 (2019).","journal-title":"Development"},{"key":"2255_CR18","doi-asserted-by":"publisher","unstructured":"Bar, S. & Benvenisty, N. Human pluripotent stem cells: derivation and applications. Nat. Rev. Mol. Cell Biol. https:\/\/doi.org\/10.1038\/S41580-020-00309-7 (2020).","DOI":"10.1038\/S41580-020-00309-7"},{"key":"2255_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.mcn.2015.11.011","volume":"73","author":"A Bhattacharyya","year":"2015","unstructured":"Bhattacharyya, A. & Zhao, X. Human pluripotent stem cell models of fragile X syndrome. Mol. Cell. Neurosci. 73, 43\u201351 (2015).","journal-title":"Mol. Cell. Neurosci."},{"key":"2255_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/genes7100077","volume":"7","author":"H Mor-Shaked","year":"2016","unstructured":"Mor-Shaked, H. & Eiges, R. Modeling fragile X syndrome using human pluripotent stem cells. Genes 7, 77 (2016).","journal-title":"Genes"},{"key":"2255_CR21","doi-asserted-by":"crossref","unstructured":"Vershkov, D., Ben-Hur, T. & Benvenisty, N. in Fragile X Syndrome: from Genetics to Targeted Treatment (eds Willemsen, R. & Kooy, R. F.) 103\u2013121 (Academic, 2017).","DOI":"10.1016\/B978-0-12-804461-2.00006-8"},{"key":"2255_CR22","doi-asserted-by":"publisher","unstructured":"Burton, A. & Torres-Padilla, M. E. Epigenome dynamics in early mammalian embryogenesis. Nat. Rev. Genet. https:\/\/doi.org\/10.1038\/s41576-025-00831-4 (2025).","DOI":"10.1038\/s41576-025-00831-4"},{"key":"2255_CR23","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.stem.2007.09.001","volume":"1","author":"R Eiges","year":"2007","unstructured":"Eiges, R. et al. Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 1, 568\u2013577 (2007).","journal-title":"Cell Stem Cell"},{"key":"2255_CR24","first-page":"407","volume":"6","author":"A Urbach","year":"2010","unstructured":"Urbach, A., Bar-Nur, O., Daley, G. Q. & Benvenisty, N. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 6, 407\u2013411 (2010).","journal-title":"Cell"},{"key":"2255_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.stem.2011.06.007","volume":"9","author":"O Bar-Nur","year":"2011","unstructured":"Bar-Nur, O., Russ, H. A., Efrat, S. & Benvenisty, N. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell 9, 17\u201323 (2011).","journal-title":"Cell Stem Cell"},{"key":"2255_CR26","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1073\/pnas.0910012107","volume":"107","author":"BY Hu","year":"2010","unstructured":"Hu, B. Y. et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc. Natl Acad. Sci. USA 107, 4335\u20134340 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2255_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.stemcr.2014.10.015","volume":"4","author":"T Halevy","year":"2015","unstructured":"Halevy, T., Czech, C. & Benvenisty, N. Molecular mechanisms regulating the defects in fragile X syndrome neurons derived from human pluripotent stem cells. Stem Cell Reports 4, 37\u201346 (2015).","journal-title":"Stem Cell Reports"},{"key":"2255_CR28","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41593-021-00913-6","volume":"24","author":"Y Kang","year":"2021","unstructured":"Kang, Y. et al. A human forebrain organoid model of fragile X syndrome exhibits altered neurogenesis and highlights new treatment strategies. Nat. Neurosci. 24, 1377\u20131391 (2021).","journal-title":"Nat. Neurosci."},{"key":"2255_CR29","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.3390\/cells11111725","volume":"11","author":"A Lee","year":"2022","unstructured":"Lee, A., Xu, J., Wen, Z. & Jin, P. Across dimensions: developing 2D and 3D human iPSC-based models of fragile X syndrome. Cells 11, 1725 (2022).","journal-title":"Cells"},{"key":"2255_CR30","doi-asserted-by":"publisher","first-page":"12718","DOI":"10.3390\/ijms252312718","volume":"25","author":"KM Gunapala","year":"2024","unstructured":"Gunapala, K. M. et al. Ascorbic acid ameliorates molecular and developmental defects in human-induced pluripotent stem cell and cerebral organoid models of fragile X syndrome. Int. J. Mol. Sci. 25, 12718 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2255_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.740574","volume":"9","author":"Y Huang","year":"2021","unstructured":"Huang, Y. et al. Research progress, challenges, and breakthroughs of organoids as disease models. Front. Cell Dev. Biol. 9, 740574 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"2255_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41589-020-00700-7","volume":"17","author":"H Shivram","year":"2020","unstructured":"Shivram, H., Cress, B. F., Knott, G. J. & Doudna, J. A. Controlling and enhancing CRISPR systems. Nat. Chem. Biol. 17, 10\u201319 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"2255_CR33","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.celrep.2015.08.084","volume":"13","author":"CY Park","year":"2015","unstructured":"Park, C. Y. et al. Reversion of FMR1 methylation and silencing by editing the triplet repeats in fragile X iPSC-derived neurons. Cell Rep. 13, 234\u2013241 (2015).","journal-title":"Cell Rep."},{"key":"2255_CR34","doi-asserted-by":"publisher","first-page":"e0165499","DOI":"10.1371\/journal.pone.0165499","volume":"11","author":"N Xie","year":"2016","unstructured":"Xie, N. et al. Reactivation of FMR1 by CRISPR\/Cas9-mediated deletion of the expanded CGG-repeat of the fragile X chromosome. PLoS ONE 11, e0165499 (2016).","journal-title":"PLoS ONE"},{"key":"2255_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-1-0716-1908-7_2","volume":"2416","author":"LA Fischer","year":"2022","unstructured":"Fischer, L. A., Khan, S. A. & Theunissen, T. W. Induction of human na\u00efve pluripotency using 5i\/L\/A medium. Methods Mol. Biol. 2416, 13\u201328 (2022).","journal-title":"Methods Mol. Biol."},{"key":"2255_CR36","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1016\/j.cell.2023.04.035","volume":"186","author":"HG Lee","year":"2023","unstructured":"Lee, H. G. et al. Site-specific R-loops induce CGG repeat contraction and fragile X gene reactivation. Cell 186, 2593\u20132609 (2023).","journal-title":"Cell"},{"key":"2255_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/embor.2011.233","volume":"13","author":"K Williams","year":"2012","unstructured":"Williams, K., Christensen, J. & Helin, K. DNA methylation: TET proteins\u2014guardians of CpG islands? EMBO Rep. 13, 28\u201335 (2012).","journal-title":"EMBO Rep."},{"key":"2255_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004630","volume":"10","author":"M Groh","year":"2014","unstructured":"Groh, M. & Gromak, N. Out of balance: R-loops in human disease. PLoS Genet. 10, e1004630 (2014).","journal-title":"PLoS Genet."},{"key":"2255_CR39","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1093\/hmg\/4.11.2103","volume":"4","author":"HJM Smeets","year":"1995","unstructured":"Smeets, H. J. M. et al. Normal phenotype in two brothers with a full FMR1 mutation. Hum. Mol. Genet. 4, 2103\u20132108 (1995).","journal-title":"Hum. Mol. Genet."},{"key":"2255_CR40","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.cell.2018.01.012","volume":"172","author":"XS Liu","year":"2018","unstructured":"Liu, X. S. et al. Rescue of fragile X syndrome neurons by DNA methylation editing of the FMR1 gene. Cell 172, 979\u2013992 (2018).","journal-title":"Cell"},{"key":"2255_CR41","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fnmol.2018.00282","volume":"11","author":"JM Haenfler","year":"2018","unstructured":"Haenfler, J. M. et al. Targeted reactivation of FMR1 transcription in fragile X syndrome embryonic stem cells. Front. Mol. Neurosci. 11, 282 (2018).","journal-title":"Front. Mol. Neurosci."},{"key":"2255_CR42","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.bbagrm.2017.08.007","volume":"1860","author":"E Tseng","year":"2017","unstructured":"Tseng, E., Tang, H. T., AlOlaby, R. R., Hickey, L. & Tassone, F. Altered expression of the FMR1 splicing variants landscape in premutation carriers. Biochim Biophys. Acta Gene Regul. Mech. 1860, 1117\u20131126 (2017).","journal-title":"Biochim Biophys. Acta Gene Regul. Mech."},{"key":"2255_CR43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2302534120","volume":"120","author":"S Shah","year":"2023","unstructured":"Shah, S. et al. Antisense oligonucleotide rescue of CGG expansion dependent FMR1 mis-splicing in fragile X syndrome restores FMRP. Proc. Natl Acad. Sci. USA 120, e2302534120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2255_CR44","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1126\/science.1245831","volume":"343","author":"D Colak","year":"2014","unstructured":"Colak, D. et al. Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. Science 343, 1002\u20131005 (2014).","journal-title":"Science"},{"key":"2255_CR45","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1159\/000329420","volume":"33","author":"SM Paluszkiewicz","year":"2011","unstructured":"Paluszkiewicz, S. M., Martin, B. S. & Huntsman, M. M. Fragile X syndrome: the GABAergic system and circuit dysfunction. Dev. Neurosci. 33, 349\u2013364 (2011).","journal-title":"Dev. Neurosci."},{"key":"2255_CR46","doi-asserted-by":"publisher","first-page":"321ra325","DOI":"10.1126\/scitranslmed.aab4109","volume":"8","author":"E Berry-Kravis","year":"2016","unstructured":"Berry-Kravis, E. et al. Mavoglurant in fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials. Sci. Transl. Med. 8, 321ra325 (2016).","journal-title":"Sci. Transl. Med."},{"key":"2255_CR47","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/JCP.0000000000001553","volume":"42","author":"MC Grabb","year":"2022","unstructured":"Grabb, M. C. & Potter, W. Z. CNS trial failures: using the fragile X syndrome-mGluR5 drug target to highlight the complexities of translating preclinical discoveries into human trials. J. Clin. Psychopharmacol. 42, 234\u2013237 (2022).","journal-title":"J. Clin. Psychopharmacol."},{"key":"2255_CR48","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41556-020-00618-1","volume":"23","author":"T Kurosaki","year":"2021","unstructured":"Kurosaki, T. et al. Loss of the fragile X syndrome protein FMRP results in misregulation of nonsense-mediated mRNA decay. Nat. Cell Biol. 23, 40\u201348 (2021).","journal-title":"Nat. Cell Biol."},{"key":"2255_CR49","doi-asserted-by":"publisher","first-page":"800","DOI":"10.5966\/sctm.2014-0278","volume":"4","author":"D Kumari","year":"2015","unstructured":"Kumari, D. et al. High-throughput screening to identify compounds that increase fragile X mental retardation protein expression in neural stem cells differentiated from fragile X syndrome patient-derived induced pluripotent stem cells. Stem Cells Transl. Med. 4, 800\u2013808 (2015).","journal-title":"Stem Cells Transl. Med."},{"key":"2255_CR50","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.celrep.2019.02.026","volume":"26","author":"D Vershkov","year":"2019","unstructured":"Vershkov, D. et al. FMR1 reactivating treatments in fragile X iPSC-derived neural progenitors in vitro and in vivo. Cell Rep. 26, 2531\u20132539 (2019).","journal-title":"Cell Rep."},{"key":"2255_CR51","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/cells11010069","volume":"11","author":"JFV Hunt","year":"2022","unstructured":"Hunt, J. F. V. et al. High throughput small molecule screen for reactivation of FMR1 in fragile X syndrome human neural cells. Cells 11, 69 (2022).","journal-title":"Cells"},{"key":"2255_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017388","volume":"6","author":"S Hagemann","year":"2011","unstructured":"Hagemann, S., Heil, O., Lyko, F. & Brueckner, B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS ONE 6, e17388 (2011).","journal-title":"PLoS ONE"},{"key":"2255_CR53","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.2217\/fon-2020-1210","volume":"17","author":"S Thota","year":"2021","unstructured":"Thota, S., Oganesian, A., Azab, M. & Griffiths, E. A. Role of cedazuridine\/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia. Future Oncol. 17, 2077\u20132087 (2021).","journal-title":"Future Oncol."},{"key":"2255_CR54","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.stemcr.2022.03.011","volume":"17","author":"D Vershkov","year":"2022","unstructured":"Vershkov, D., Yilmaz, A., Yanuka, O., Nielsen, A. L. & Benvenisty, N. Genome-wide screening for genes involved in the epigenetic basis of fragile X syndrome. Stem Cell Reports 17, 1048\u20131058 (2022).","journal-title":"Stem Cell Reports"},{"key":"2255_CR55","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/jmg.32.3.162","volume":"32","author":"JC Mulley","year":"1995","unstructured":"Mulley, J. C. et al. FRAXE and mental retardation. J. Med. Genet. 32, 162\u2013169 (1995).","journal-title":"J. Med. Genet."},{"key":"2255_CR56","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/ng0596-105","volume":"13","author":"J Gecz","year":"1996","unstructured":"Gecz, J., Gedeon, A. K., Sutherland, G. R. & Mulley, J. C. Identification of the gene FMR2, associated with FRAXE mental retardation. Nat. Genet. 13, 105\u2013108 (1996).","journal-title":"Nat. Genet."},{"key":"2255_CR57","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/jmg.37.6.415","volume":"37","author":"SA Youings","year":"2000","unstructured":"Youings, S. A. et al. FRAXA and FRAXE: the results of a five-year survey. J. Med. Genet. 37, 415\u2013421 (2000).","journal-title":"J. Med. Genet."},{"key":"2255_CR58","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrneurol.2009.26","volume":"5","author":"JB Schulz","year":"2009","unstructured":"Schulz, J. B. et al. Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat. Rev. Neurol. 5, 222\u2013234 (2009).","journal-title":"Nat. Rev. Neurol."},{"key":"2255_CR59","doi-asserted-by":"publisher","first-page":"119809","DOI":"10.1016\/j.bbamcr.2024.119809","volume":"1871","author":"V Mosbach","year":"2024","unstructured":"Mosbach, V. & Puccio, H. A multiple animal and cellular models approach to study frataxin deficiency in Friedreich ataxia. Biochim. Biophys. Acta Mol. Cell Res. 1871, 119809 (2024).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"2255_CR60","doi-asserted-by":"publisher","first-page":"836476","DOI":"10.3389\/fnins.2022.836476","volume":"16","author":"AM Schreiber","year":"2022","unstructured":"Schreiber, A. M., Li, Y., Chen, Y. H., Napierala, J. S. & Napierala, M. Selected histone deacetylase inhibitors reverse the Frataxin transcriptional defect in a novel Friedreich\u2019s ataxia induced pluripotent stem cell-derived neuronal reporter system. Front. Neurosci. 16, 836476 (2022).","journal-title":"Front. Neurosci."},{"key":"2255_CR61","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrg3897","volume":"16","author":"MJ Lyst","year":"2015","unstructured":"Lyst, M. J. & Bird, A. Rett syndrome: a complex disorder with simple roots. Nat. Rev. Genet. 16, 261\u2013274 (2015).","journal-title":"Nat. Rev. Genet."},{"key":"2255_CR62","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41572-024-00568-0","volume":"10","author":"WA Gold","year":"2024","unstructured":"Gold, W. A. et al. Rett syndrome. Nat. Rev. Dis. Primers 10, 84 (2024).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2255_CR63","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add4666","volume":"15","author":"J Qian","year":"2023","unstructured":"Qian, J. et al. Multiplex epigenome editing of MECP2 to rescue Rett syndrome neurons. Sci. Transl. Med. 15, eadd4666 (2023).","journal-title":"Sci. Transl. Med."},{"key":"2255_CR64","doi-asserted-by":"publisher","first-page":"e2346","DOI":"10.1038\/cddis.2016.245","volume":"7","author":"A Pescatore","year":"2016","unstructured":"Pescatore, A., Esposito, E., Draber, P., Walczak, H. & Ursini, M. V. NEMO regulates a cell death switch in TNF signaling by inhibiting recruitment of RIPK3 to the cell death-inducing complex II. Cell Death Dis. 7, e2346 (2016).","journal-title":"Cell Death Dis."},{"key":"2255_CR65","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/hmg\/5.11.1777","volume":"5","author":"JE Parrish","year":"1996","unstructured":"Parrish, J. E., Scheuerle, A. E., Lewis, R. A., Levy, M. L. & Nelson, D. L. Selection against mutant alleles in blood leukocytes is a consistent feature in incontinentia pigmenti type 2. Hum. Mol. Genet. 5, 1777\u20131783 (1996).","journal-title":"Hum. Mol. Genet."},{"key":"2255_CR66","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1086\/324591","volume":"69","author":"S Kenwrick","year":"2001","unstructured":"Kenwrick, S. et al. Survival of male patients with incontinentia pigmenti carrying a lethal mutation can be explained by somatic mosaicism or Klinefelter syndrome. Am. J. Hum. Genet. 69, 1210\u20131217 (2001).","journal-title":"Am. J. Hum. Genet."},{"key":"2255_CR67","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jaad.2006.09.019","volume":"56","author":"F Fusco","year":"2007","unstructured":"Fusco, F., Fimiani, G., Tadini, G., Michele, D. & Ursini, M. V. Clinical diagnosis of incontinentia pigmenti in a cohort of male patients. J. Am. Acad. Dermatol. 56, 264\u2013267 (2007).","journal-title":"J. Am. Acad. Dermatol."},{"key":"2255_CR68","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/35047554","volume":"2","author":"W Reik","year":"2001","unstructured":"Reik, W. & Walter, J. Genomic imprinting: parental influence on the genome. Nat. Rev. Genet. 2, 21\u201332 (2001).","journal-title":"Nat. Rev. Genet."},{"key":"2255_CR69","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrneurol.2016.133","volume":"12","author":"K Buiting","year":"2016","unstructured":"Buiting, K., Williams, C. & Horsthemke, B. Angelman syndrome \u2014 insights into a rare neurogenetic disorder. Nat. Rev. Neurol. 12, 584\u2013593 (2016).","journal-title":"Nat. Rev. Neurol."},{"key":"2255_CR70","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/adc.2010.190165","volume":"96","author":"EL Wakeling","year":"2011","unstructured":"Wakeling, E. L. Silver\u2013Russell syndrome. Arch. Dis. Child. 96, 1156\u20131161 (2011).","journal-title":"Arch. Dis. Child."},{"key":"2255_CR71","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/gim.0b013e31822bead0","volume":"14","author":"SB Cassidy","year":"2012","unstructured":"Cassidy, S. B., Schwartz, S., Miller, J. L. & Driscoll, D. J. Prader\u2013Willi syndrome. Genet. Med. 14, 10\u201326 (2012).","journal-title":"Genet. Med."},{"key":"2255_CR72","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s00125-013-2832-1","volume":"56","author":"LE Docherty","year":"2013","unstructured":"Docherty, L. E. et al. Clinical presentation of 6q24 transient neonatal diabetes mellitus (6q24 TNDM) and genotype\u2013phenotype correlation in an international cohort of patients. Diabetologia 56, 758\u2013762 (2013).","journal-title":"Diabetologia"},{"key":"2255_CR73","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/ajmg.c.30267","volume":"154C","author":"S Choufani","year":"2010","unstructured":"Choufani, S., Shuman, C. & Weksberg, R. Beckwith\u2013Wiedemann syndrome. Am. J. Med. Genet. C Semin. Med. Genet. 154C, 343\u2013354 (2010).","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"2255_CR74","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature10726","volume":"481","author":"HS Huang","year":"2011","unstructured":"Huang, H. S. et al. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature 481, 185\u2013191 (2011).","journal-title":"Nature"},{"key":"2255_CR75","doi-asserted-by":"publisher","first-page":"5558","DOI":"10.1038\/s41467-024-49788-8","volume":"15","author":"H Vihma","year":"2024","unstructured":"Vihma, H. et al. Ube3a unsilencer for the potential treatment of Angelman syndrome. Nat. Commun. 15, 5558 (2024).","journal-title":"Nat. Commun."},{"key":"2255_CR76","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41586-020-2835-2","volume":"587","author":"JM Wolter","year":"2020","unstructured":"Wolter, J. M. et al. Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA. Nature 587, 281\u2013284 (2020).","journal-title":"Nature"},{"key":"2255_CR77","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142574","volume":"131","author":"RS Schmid","year":"2021","unstructured":"Schmid, R. S. et al. CRISPR\/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice. J. Clin. Invest. 131, e142574 (2021).","journal-title":"J. Clin. Invest."},{"key":"2255_CR78","volume":"5","author":"D Rohm","year":"2025","unstructured":"Rohm, D. et al. Activation of the imprinted Prader\u2013Willi syndrome locus by CRISPR-based epigenome editing. Cell Genom. 5, 100770 (2025).","journal-title":"Cell"},{"key":"2255_CR79","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1038\/s41380-023-02208-7","volume":"28","author":"SE Wang","year":"2023","unstructured":"Wang, S. E. & Jiang, Y.-H. Novel epigenetic molecular therapies for imprinting disorders. Mol. Psychiatry 28, 3182\u20133193 (2023).","journal-title":"Mol. Psychiatry"},{"key":"2255_CR80","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/ejhg.2008.61","volume":"16","author":"KB Garber","year":"2008","unstructured":"Garber, K. B., Visootsak, J. & Warren, S. T. Fragile X syndrome. Eur. J. Hum. Genet. 16, 666\u2013672 (2008).","journal-title":"Eur. J. Hum. Genet."},{"key":"2255_CR81","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/ejhg.2009.51","volume":"17","author":"L Rodriguez-Revenga","year":"2009","unstructured":"Rodriguez-Revenga, L. et al. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur. J. Hum. Genet. 17, 1359\u20131362 (2009).","journal-title":"Eur. J. Hum. Genet."},{"key":"2255_CR82","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1086\/302720","volume":"66","author":"F Tassone","year":"2000","unstructured":"Tassone, F. et al. Elevated levels of FMR1 mRNA carrier males: a new mechanism of involvement in the fragile-X syndrome. Am. J. Hum. Genet. 66, 6\u201315 (2000).","journal-title":"Am. J. Hum. Genet."},{"key":"2255_CR83","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1261\/rna.280807","volume":"13","author":"F Tassone","year":"2007","unstructured":"Tassone, F. et al. Elevated FMR1 mRNA in premutation carriers is due to increased transcription. RNA 13, 555\u2013562 (2007).","journal-title":"RNA"},{"key":"2255_CR84","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/dmcn.13985","volume":"61","author":"CM Kraan","year":"2019","unstructured":"Kraan, C. M., Godler, D. E. & Amor, D. J. Epigenetics of fragile X syndrome and fragile X-related disorders. Dev. Med. Child Neurol. 61, 121\u2013127 (2019).","journal-title":"Dev. Med. Child Neurol."},{"key":"2255_CR85","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/jmg.30.1.53","volume":"30","author":"SJ Landy","year":"1993","unstructured":"Landy, S. J. & Donnai, D. Incontinentia pigmenti (Bloch\u2013Sulzberger syndrome). J. Med. Genet. 30, 53\u201359 (1993).","journal-title":"J. Med. Genet."},{"key":"2255_CR86","volume":"15","author":"UP Vaghani","year":"2023","unstructured":"Vaghani, U. P. et al. Bloch\u2013Sulzberger syndrome: a rare X-linked dominant genetic disorder in a newborn. Cureus 15, e48823 (2023).","journal-title":"Cureus"},{"key":"2255_CR87","doi-asserted-by":"publisher","first-page":"R107","DOI":"10.1093\/hmg\/ddaa133","volume":"29","author":"R Prasasya","year":"2020","unstructured":"Prasasya, R., Grotheer, K. V., Siracusa, L. D. & Bartolomei, M. S. Temple syndrome and Kagami\u2013Ogata syndrome: clinical presentations, genotypes, models and mechanisms. Hum. Mol. Genet. 29, R107\u2013R116 (2020).","journal-title":"Hum. Mol. Genet."},{"key":"2255_CR88","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13148-024-01652-8","volume":"16","author":"N Baena","year":"2024","unstructured":"Baena, N. et al. Novel 14q32.2 paternal deletion encompassing the whole DLK1 gene associated with Temple syndrome. Clin. Epigenetics 16, 62 (2024).","journal-title":"Clin. Epigenetics"}],"container-title":["Nature Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02255-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02255-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02255-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T08:32:29Z","timestamp":1757233949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02255-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":88,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2255"],"URL":"https:\/\/doi.org\/10.1038\/s41588-025-02255-6","relation":{},"ISSN":["1061-4036","1546-1718"],"issn-type":[{"value":"1061-4036","type":"print"},{"value":"1546-1718","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}